Results 51 to 60 of about 31,625 (291)

Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Hypomethylating agents (HMA) and allogeneic hematopoietic stem cell transplantation (alloHSCT) have both demonstrated remissions in VEXAS; however, comparative data is lacking. We conducted a multicenter, retrospective analysis of 66 patients diagnosed with VEXAS syndrome treated with HMA (n = 35) or alloHSCT (n = 31). Baseline characteristics
Saubia Fathima   +48 more
wiley   +1 more source

Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs Do Not Arrest Bone Loss in Patients With Rheumatoid Arthritis: A Long‐Term Multicenter Observational Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective Osteoporosis causes fractures that further increase the disease burden of rheumatoid arthritis (RA); however, osteoporosis treatment rates remain low. Although several studies have reported that biologic or targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) can prevent or improve osteoporosis in RA, our large‐scale, real ...
Takafumi Aritomi   +30 more
wiley   +1 more source

Haemovigilance: A Current Update in Indian Perspective [PDF]

open access: yesJournal of Clinical and Diagnostic Research, 2016
Haemovigilance is an organised scheme of monitoring, identifying, reporting, investigating and analysing adverse events and reactions pertinent to transfusion and manufacturing blood products.
Somnath Mukherjee, Rituparna Maiti
doaj   +1 more source

Spectrum of hemolytic transfusion reactions from tertiary cancer center over a 1-year period

open access: yesGlobal Journal of Transfusion Medicine, 2023
Background and Objectives: Acute hemolytic transfusion reactions (HTRs) one of the serious adverse events manifesting within 24 h of blood transfusion. To review the adverse transfusion reactions in our cancer center over a 1-year period, especially HTR ...
Valathuparambil Jalaludheen Fathima   +2 more
doaj   +1 more source

Adverse events in bedaquiline‐ and pretomanid‐based regimens for drug‐resistant tuberculosis from trial, implementation and pharmacovigilance studies

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract The availability of safety data, particularly concerning adverse events (AEs) associated with the new shorter regimen for drug‐resistant tuberculosis (TB) containing a bedaquiline–pretomanid‐based regimen, is still limited. This systematic review aims to provide a comprehensive and updated analysis of AEs related to this new regimen by ...
Nisa Maria   +4 more
wiley   +1 more source

TRAckERS: Transfusion-Related Adverse Events Reporting System [PDF]

open access: yes, 2018
This study examine the efficiency and effectiveness of the procedure of reporting the transfusion-related adverse events. Blood transfusion is a process of receiving blood through an intravenous (IV) line from patient’s blood vessels. It is considered as
Toh, Shi Yin   +4 more
core  

Risk of venous thromboembolism after SARS‐CoV‐2 vaccination—Evidence from genome‐wide association study and population‐based observational study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim We aimed to investigate whether genetic variation is associated with venous thromboembolism after immunization with SARS‐CoV‐2 vaccines. Methods We conducted a genome‐wide association study (GWAS) on cases of venous thromboembolism within 42 days after SARS‐CoV‐2 vaccination, recruited from reports of adverse drug reactions sent to the Swedish ...
Sofia Attelind   +7 more
wiley   +1 more source

Evaluating effectiveness of risk minimization through healthcare professional surveys: A review of post‐authorization studies, 2022–2024

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Risk minimization measures (RMMs) are key regulatory tools to ensure safe medicinal product use. Regulatory guidelines recommend pre‐specifying the targets, or ‘thresholds’, for assessing RMM effectiveness. We aimed to review recent industry‐sponsored post‐authorization safety studies (PASS) that evaluated the effectiveness of RMMs ...
Kexin Zhu   +7 more
wiley   +1 more source

Harnessing blood clot as a native scaffold for orchestrating tissue repairs and regeneration

open access: yesBMEMat, EarlyView.
The blood clot, owing to its dynamic composition and unique microenvironment, holds significant yet underappreciated potential for tissue engineering. This review systematically summarizes the pathophysiology of clot formation, the key regulatory factors shaping its microenvironment, and its applications in both pre‐clinical and clinical settings ...
Gao‐peng Dang   +13 more
wiley   +1 more source

Dissecting the complexity of pediatric blood transfusions and risk of adverse reactions in Aotearoa New Zealand: Pediatric transfusions and adverse reaction risk in NZ

open access: yesBlood Transfusion, 2022
Background - Children have different clinical and physiological drivers for transfusion from adult recipients. However, adverse transfusion reactions (ATRs) in pediatric patients are usually reported using the same criteria as for adults. Broad assessments of pediatric ATRs neglect substantial variation in different developmental stages.
Wei, Wen-Hua   +3 more
openaire   +1 more source

Home - About - Disclaimer - Privacy